No abstract available
Keywords:
Chronic inflammatory demyelinating polyneuropathy; Guillain–Barre syndrome; Immunotherapy; Melanoma.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Azetidines / administration & dosage
-
Azetidines / adverse effects
-
Brain Neoplasms / drug therapy
-
Demyelinating Diseases / chemically induced*
-
Demyelinating Diseases / complications
-
Female
-
Guillain-Barre Syndrome / chemically induced*
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
MAP Kinase Kinase Kinases / antagonists & inhibitors
-
Melanoma / drug therapy*
-
Melanoma / pathology
-
Middle Aged
-
Piperidines / administration & dosage
-
Piperidines / adverse effects
-
Polyradiculoneuropathy / chemically induced*
-
Polyradiculoneuropathy / complications
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Sulfonamides / administration & dosage
-
Sulfonamides / adverse effects
-
Vemurafenib
Substances
-
Azetidines
-
Indoles
-
Piperidines
-
Protein Kinase Inhibitors
-
Sulfonamides
-
Vemurafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
MAP Kinase Kinase Kinases
-
cobimetinib